D'ALESSIO, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 693
AS - Asia 690
EU - Europa 467
SA - Sud America 61
AF - Africa 41
Continente sconosciuto - Info sul continente non disponibili 36
Totale 1.988
Nazione #
US - Stati Uniti d'America 645
RU - Federazione Russa 228
SG - Singapore 212
CN - Cina 105
HK - Hong Kong 101
BD - Bangladesh 92
IT - Italia 74
VN - Vietnam 73
BR - Brasile 43
DE - Germania 36
FR - Francia 34
BJ - Benin 31
IN - India 28
KR - Corea 27
GB - Regno Unito 25
CA - Canada 23
AT - Austria 19
MX - Messico 18
ES - Italia 10
IQ - Iraq 10
JP - Giappone 10
AR - Argentina 9
PL - Polonia 9
FI - Finlandia 6
LT - Lituania 6
NL - Olanda 5
PH - Filippine 5
TR - Turchia 5
ZA - Sudafrica 5
EC - Ecuador 4
UA - Ucraina 4
PK - Pakistan 3
SE - Svezia 3
TW - Taiwan 3
CH - Svizzera 2
EG - Egitto 2
ID - Indonesia 2
JM - Giamaica 2
LB - Libano 2
MA - Marocco 2
PY - Paraguay 2
SA - Arabia Saudita 2
SY - Repubblica araba siriana 2
BE - Belgio 1
BS - Bahamas 1
CL - Cile 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GF - Guiana Francese 1
HN - Honduras 1
KG - Kirghizistan 1
KH - Cambogia 1
MY - Malesia 1
NP - Nepal 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
TN - Tunisia 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 1.952
Città #
San Jose 142
Hong Kong 99
Singapore 92
Ashburn 87
Council Bluffs 59
Beijing 39
Los Angeles 33
Cotonou 31
Columbus 28
Moscow 26
Santa Clara 26
Lauterbourg 21
New York 18
Seoul 18
Hanoi 17
Buffalo 15
Falkenstein 15
Ho Chi Minh City 15
Brooklyn 11
Mexico City 11
St Louis 10
Dallas 9
Orem 9
Gangbuk-gu 8
São Paulo 8
Tokyo 8
Vienna 8
Warsaw 8
Chennai 7
London 7
Novara 7
Toronto 7
Assago 6
Da Nang 6
Frankfurt am Main 6
Nuremberg 6
Haiphong 5
Milan 5
Montreal 5
Mumbai 5
Phoenix 5
Poplar 5
Tianjin 5
Boston 4
Denver 4
Dhaka 4
Florence 4
Johannesburg 4
Manila 4
Shanghai 4
Ankara 3
Atlanta 3
Baghdad 3
Casier 3
Curitiba 3
Hangzhou 3
Helsinki 3
Long Xuyen 3
Palermo 3
Quito 3
Seattle 3
Stockholm 3
Turin 3
Augusta 2
Baie-D'Urfé 2
Bengaluru 2
Bologna 2
Botucatu 2
Bragança Paulista 2
Buenos Aires 2
Can Tho 2
Catania 2
Cedar Park 2
Charlotte 2
Chicago 2
Cleveland 2
Córdoba 2
Delhi 2
Elk Grove Village 2
Figino 2
Genoa 2
Hillsboro 2
Jakarta 2
Lakeland 2
Lecce 2
Madrid 2
Manchester 2
Mosul 2
Naples 2
Philadelphia 2
Pittsburgh 2
Providence 2
Pune 2
Querétaro 2
Raleigh 2
Redondo Beach 2
Richmond 2
Sabará 2
Sona 2
The Bronx 2
Totale 1.099
Nome #
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 130
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 129
Immunotherapy vs Best Supportive Care for Patients with Hepatocellular Cancer with Child-Pugh B Dysfunction 111
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 108
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 102
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 100
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 98
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis 91
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 81
The price and value of therapeutic synergy in liver cancer 80
Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison 80
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis 76
Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma 75
New Scenarios in Liver Transplantation for Hepatocellular Carcinoma 74
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events 71
ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular Cancer 68
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 66
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction-Reply 65
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study 65
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden 62
Diabetes and Immune Checkpoint Inhibitors—Response 62
Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma 59
Immunotherapy at all stages of hepatocellular carcinoma 58
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 41
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 36
Totale 1.988
Categoria #
all - tutte 6.893
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.893


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025400 5 0 5 2 4 7 45 106 98 37 13 78
2025/20261.441 56 33 48 120 192 102 205 182 119 164 77 143
2026/2027147 59 88 0 0 0 0 0 0 0 0 0 0
Totale 1.988